Cargando…
Drug induced rhabdomyolysis
Rhabdomyolysis is a clinical condition of potential life threatening destruction of skeletal muscle caused by diverse mechanisms including drugs and toxins. Given the fact that structurally not related compounds cause an identical phenotype pinpoints to common targets or pathways, responsible for ex...
Autor principal: | |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Science Ltd
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3387368/ https://www.ncbi.nlm.nih.gov/pubmed/22560920 http://dx.doi.org/10.1016/j.coph.2012.04.002 |
_version_ | 1782237092657496064 |
---|---|
author | Hohenegger, Martin |
author_facet | Hohenegger, Martin |
author_sort | Hohenegger, Martin |
collection | PubMed |
description | Rhabdomyolysis is a clinical condition of potential life threatening destruction of skeletal muscle caused by diverse mechanisms including drugs and toxins. Given the fact that structurally not related compounds cause an identical phenotype pinpoints to common targets or pathways, responsible for executing rhabdomyolysis. A drop in myoplasmic ATP paralleled with sustained elevations in cytosolic Ca(2+) concentration represents a common signature of rhabdomyolysis. Interestingly, cardiac tissue is hardly affected or only secondary, as a consequence of imbalance in electrolytes or acid–base equilibrium. This dogma is now impaired by compounds, which show up with combined toxicity in heart and skeletal muscle. In this review, cases of rhabdomyolysis with novel recently approved drugs will be explored for new target mechanisms in the light of previously described pathomechanisms. |
format | Online Article Text |
id | pubmed-3387368 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Elsevier Science Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-33873682012-07-05 Drug induced rhabdomyolysis Hohenegger, Martin Curr Opin Pharmacol Article Rhabdomyolysis is a clinical condition of potential life threatening destruction of skeletal muscle caused by diverse mechanisms including drugs and toxins. Given the fact that structurally not related compounds cause an identical phenotype pinpoints to common targets or pathways, responsible for executing rhabdomyolysis. A drop in myoplasmic ATP paralleled with sustained elevations in cytosolic Ca(2+) concentration represents a common signature of rhabdomyolysis. Interestingly, cardiac tissue is hardly affected or only secondary, as a consequence of imbalance in electrolytes or acid–base equilibrium. This dogma is now impaired by compounds, which show up with combined toxicity in heart and skeletal muscle. In this review, cases of rhabdomyolysis with novel recently approved drugs will be explored for new target mechanisms in the light of previously described pathomechanisms. Elsevier Science Ltd 2012-06 /pmc/articles/PMC3387368/ /pubmed/22560920 http://dx.doi.org/10.1016/j.coph.2012.04.002 Text en © 2012 Elsevier Ltd. https://creativecommons.org/licenses/by-nc-nd/3.0/ Open Access under CC BY-NC-ND 3.0 (https://creativecommons.org/licenses/by-nc-nd/3.0/) license |
spellingShingle | Article Hohenegger, Martin Drug induced rhabdomyolysis |
title | Drug induced rhabdomyolysis |
title_full | Drug induced rhabdomyolysis |
title_fullStr | Drug induced rhabdomyolysis |
title_full_unstemmed | Drug induced rhabdomyolysis |
title_short | Drug induced rhabdomyolysis |
title_sort | drug induced rhabdomyolysis |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3387368/ https://www.ncbi.nlm.nih.gov/pubmed/22560920 http://dx.doi.org/10.1016/j.coph.2012.04.002 |
work_keys_str_mv | AT hoheneggermartin druginducedrhabdomyolysis |